Author

Lisa Marie Barroilhet

University of Wisconsin–MadisonORCID 0000-0001-9315-2414Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Manish S. PatankariD· 2 shared Alexa R. HeatoniD· 1 shared Andrea PennatiiD· 1 shared Aurora D’AmatoiD· 1 shared Catigan A. HedicaniD· 1 shared Jacques GalipeauiD· 1 shared Mayra A. Betancourt PonceiD· 1 shared Melissa C. SkalaiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Manish S. PatankarORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintMay 8, 2026

An autologous cell-based therapeutic vaccine expressing IL6/1 fusokine drives robust anti-tumor response against ovarian cancer.

Sejal Sharma, Rahul Das, Andrea Pennati…·Jacques Galipeau

This paper develops an IL6/1 fusokine that enhances T cell survival and anti-tumor response in a preclinical ovarian cancer model.

DOI 10.64898/2026.05.05.721149

mouseproteomics

𝕏 PostBluesky

Cancer BiologyJournal of Investigative DermatologyPeer-reviewedMar 24, 2026

Atovaquone-induced therapeutic rewiring of melanoma metabolism

Mayra A. Betancourt Ponce, Alexa R. Heaton, Samantha K. Burkard…·Lisa Marie Barroilhet

This study shows atovaquone inhibits OXPHOS and glycolysis in melanoma, causing metabolic reprogramming, oxidative stress, and reduced tumor growth in vitro and in vivo.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky